Loading...
XSHE
003017
Market cap362mUSD
Dec 05, Last price  
30.47CNY
1D
2.73%
1Q
-12.89%
IPO
-33.31%
Name

Zhejiang Dayang Biotech Group Co Ltd

Chart & Performance

D1W1MN
XSHE:003017 chart
P/E
40.15
P/S
2.81
EPS
0.76
Div Yield, %
1.48%
Shrs. gr., 5y
-0.47%
Rev. gr., 5y
7.91%
Revenues
910m
-1.03%
499,724,931458,565,579448,098,833441,234,459554,719,478584,159,118621,750,703678,335,140783,209,2771,058,104,944919,451,375909,955,718
Net income
64m
+27.48%
26,321,79928,071,64623,666,15528,815,47150,256,35570,796,60279,497,18391,606,02670,009,32380,726,94850,006,70463,746,331
CFO
66m
-63.71%
91,644,61957,730,23148,950,95984,631,60048,638,31538,774,402113,092,957112,488,116091,886,561182,422,54366,193,958
Dividend
Jul 11, 20240.45 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Dayang Biology Technology Co.,Ltd. engages in research and development, production, and sale of biological products, agricultural chemicals, and chemical in China and internationally. The company's products include food additive potassium carbonate, potassium carbonate, food additive potassium bicarbonate, potassium bicarbonate, agricultural grade ammonium chloride, and industrial grade ammonium chloride. It also offers chemical products, such as 2-chloro-6-fiuorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and anisole products; veterinary APIs, including amprolium HCL; and veterinary drug premixes comprising enramycin premixes. The company was founded in 1976 and is based in Jiande, China.
IPO date
Oct 26, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑00
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT